Zealand Pharma 132 0 Kommentare

Press Release – No. 53 / 2020

Zealand Pharma to participate in upcoming investor conferences

Copenhagen, DK November 10, 2020 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in November:

Bryan, Garnier & Co European Healthcare Conference
Date: Monday, November 16, 2020

Jefferies Virtual London Healthcare Conference
Date: Tuesday, November 17, 2020
Fireside chat: 10:15 a.m. ET/ 3:15 p.m. GMT/ 4:15 p.m. CET

Nordea Innovation Seminar
Date: Wednesday, November 25/26, 2020

A live webcast of the Jefferies event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.

Lesen Sie auch

Rallye, Abverkauf, Neustart?

Der Wahnsinn hat einen Namen – Cannabis!

heute 14:00

Community-Rückblick

wO-User zu Bullrun & Blitzcrash bei Newron: "Wieso darf der Kurs nicht steigen?"

heute 11:00

Abnehmspritzen in Planung

Kursexplosion: Nicht Apple, sondern Amgen wird heute den Dow Jones anführen!

gestern 09:05

Cybersecurity

Diese Aktien und ETFs profitieren vom 166,2 Mrd. US-Dollar Wachstumsmarkt

heute 16:00

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

For further information, please contact:

Mads Kronborg
Head of Investor Relations & Communication
Phone: +45 5060 3707
Email: mkronborg@zealandpharma.com

For U.S. Media
David Rosen
Argot Partners
Phone: 212-600-1902
Email: media@zealandpharma.com